Overview

Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

Status:
Recruiting
Trial end date:
2022-01-17
Target enrollment:
0
Participant gender:
Female
Summary
This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly emetogenic chemotherapy.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Instituto Brasileiro de Controle do Cancer
Treatments:
Olanzapine
Criteria
Inclusion Criteria:

- Breast cancer hitologically confirmed

- 18 Years and older (Adult, Older Adult)

- Patients about to start use of Doxorubicine 60mg/m2 + Cyclophosfamide 600mg/m2

- No previous chemotherapy for breast cancer

Exclusion Criteria:

- Patients not capable of completing the questionnaire

- Patients with other condition that could cause nausea and emesis

- Use of opioids

- Use of antipsychotic medications

- Patients not capable of taking medications orally